ArticleCancer discovery2022

Correction: Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer.

PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.